Novo Nordisk partners with Swiss biotech firm on obesity – zebrafish to unlock new drugs
Novo Nordisk is teaming up with Swiss start-up Eracal Therapeutics, which is specialized in discovering new drugs from a zebrafish larvae platform. The firms will develop treatments targeted at food intake and other factors associated with obesity.
by ALBERT RØNNING-ANDERSSON, translated by daniel pedersem
A new research collaboration between Novo Nordisk and a start-up from Switzerland, Eracal Therapeutics, has seen the light of day, a company press release announces.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Novo Nordisk settles securities lawsuit in Denmark
For subscribers
